<DOC>
	<DOCNO>NCT00678964</DOCNO>
	<brief_summary>60 % malignant disease occur patient 65 year old . For patient , aggressive treatment often suitable due reduce life-expectancy , reduce general condition , comorbidities , reduce vital function lead increased adverse effect chemotherapy . Therefore , important investigate alternative therapy option elderly patient . Erlotinib orally apply medication associate reasonable toxicity . This targeted agent may prove effective well-tolerated first-line therapy elderly patient advance non small cell lung cancer . Therefore , aim study investigate progression-free survival combination vinorelbine carboplatin comparison erlotinib . Given significant reduction efficiency may provide elderly patient 70 year age active oral substance without subject sometimes severe adverse effect chemotherapy .</brief_summary>
	<brief_title>Erlotinib Versus Carboplatin/Vinorelbine Elderly Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytological proven NSCLC , stage lll b ( pleural effusion ) stage lV . Tumour locally advance suitable surgery radiotherapy indicate . Neither cytostatic immunological pretreatment Age &gt; 70 year At least one measurable lesion ( RECIST criterion ) previously irradiate ECOG Performance Status 01 Life expectancy &gt; 3 month Adequate bone marrow function : ANC &gt; 1.5 x 109/L , Platelets &gt; 100 x 109/L Adequate liver function : Total Bilirubin &lt; 1.5 x ULN , GOT/GPT &lt; 3 x ULN ( existent liver metastasis &lt; 5 x ULN ) Adequate renal function : creatinine clearance &gt; 45 ml/min ( calculate accord CockroftGault ) Fertile men must agree use effective method birth control participate study Signed write informed consent Uncontrolled metastasis CNS Acute , heavy uncontrolled infection Any serious concomitant disease medical condition , could interfere participate study Severe hypersensitivity Erlotinib component Hypersensitivity Carboplatin and/or platinum compound Hypersensitivity Vinorelbin Vincaalkaloids Patients history active malignancy past 5 year ( exception carcinoma situ cervix , non melanomatous skin cancer local prostate carcinoma surgically treat successfully ) exclude . Participation another clinical trial investigational drug time within 30 day prior registration Psychological , familial , social geographical situation limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Elderly patient</keyword>
</DOC>